The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II multicenter, randomized, placebo-controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC).
 
Benjamin Philip Levy
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Celgene; Genentech/Roche; Lilly; Pfizer
Speakers' Bureau - Genentech/Roche; Lilly
 
Giuseppe Giaccone
Consulting or Advisory Role - Astex Pharmaceuticals; Boehringer Ingelheim; Celgene; Clovis Oncology; Inivata
Research Funding - AstraZeneca; Karyopharm Therapeutics
 
Benjamin Besse
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Inivata (Inst); Lilly (Inst); Onxeo (Inst); ose pharma (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Medarex; Novartis; Pfizer; Pierre Fabre; Roche
 
Damir Begic
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Xiaoling Wu
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Abderrahim Fandi
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Luis Paz-Ares
Stock and Other Ownership Interests - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; HSD; Novartis; Pfizer; Roche/Genentech